ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; ...
Third Quarter 2025 YoY Highlights: Net Sales: $1.04 billion, down 4.1% year-over-year as favorable currency translation (+1.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback